Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale

Charles J. Ryan; Amy M. Lin; Eric J. Small

doi:10.1016/j.urolonc.2005.11.021

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale

Charles J. Ryan, Amy M. Lin, Eric J. Small

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

Angiogenesis inhibition with bevacizumab and other agents of this class are showing significant activity in a variety of cancers. In prostate cancer, the single agent activity has been low, but the addition of these agents to chemotherapy may be the area in which they provide their greatest clinical benefit. An ongoing study conducted by the Cancer and Leukemia Group B will test this approach in men with metastatic hormone refractory prostate cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage disease as well as in combination with other approaches. This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies.

Original language	English (US)
Pages (from-to)	250-253
Number of pages	4
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	24
Issue number	3
DOIs	https://doi.org/10.1016/j.urolonc.2005.11.021
State	Published - May 2006
Externally published	Yes

Bibliographical note

Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.

Keywords

Angiogenesis inhibitors
Bevacizumab
Hormone refractory prostate cancer
Prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.urolonc.2005.11.021

OpenUrl availability

Full text

Cite this

@article{6da9860786b84650bc515d96306be028,

title = "Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale",

abstract = "Angiogenesis inhibition with bevacizumab and other agents of this class are showing significant activity in a variety of cancers. In prostate cancer, the single agent activity has been low, but the addition of these agents to chemotherapy may be the area in which they provide their greatest clinical benefit. An ongoing study conducted by the Cancer and Leukemia Group B will test this approach in men with metastatic hormone refractory prostate cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage disease as well as in combination with other approaches. This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies.",

keywords = "Angiogenesis inhibitors, Bevacizumab, Hormone refractory prostate cancer, Prostate cancer",

author = "Ryan, {Charles J.} and Lin, {Amy M.} and Small, {Eric J.}",

year = "2006",

month = may,

doi = "10.1016/j.urolonc.2005.11.021",

language = "English (US)",

volume = "24",

pages = "250--253",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer

T2 - History and rationale

AU - Ryan, Charles J.

AU - Lin, Amy M.

AU - Small, Eric J.

PY - 2006/5

Y1 - 2006/5

N2 - Angiogenesis inhibition with bevacizumab and other agents of this class are showing significant activity in a variety of cancers. In prostate cancer, the single agent activity has been low, but the addition of these agents to chemotherapy may be the area in which they provide their greatest clinical benefit. An ongoing study conducted by the Cancer and Leukemia Group B will test this approach in men with metastatic hormone refractory prostate cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage disease as well as in combination with other approaches. This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies.

AB - Angiogenesis inhibition with bevacizumab and other agents of this class are showing significant activity in a variety of cancers. In prostate cancer, the single agent activity has been low, but the addition of these agents to chemotherapy may be the area in which they provide their greatest clinical benefit. An ongoing study conducted by the Cancer and Leukemia Group B will test this approach in men with metastatic hormone refractory prostate cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage disease as well as in combination with other approaches. This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies.

KW - Angiogenesis inhibitors

KW - Bevacizumab

KW - Hormone refractory prostate cancer

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33646172081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646172081&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.11.021

DO - 10.1016/j.urolonc.2005.11.021

M3 - Review article

C2 - 16678059

AN - SCOPUS:33646172081

SN - 1078-1439

VL - 24

SP - 250

EP - 253

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 3

ER -

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this